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Abstract
Autism is a severe neurodevelopmental disorder, diagnosed on the basis of core behavioral
symptoms. Although the mechanistic basis for the disorder is not yet known, genetic analyses
have suggested a role for abnormal excitatory/inhibitory signaling systems in brain, including
dysregulation of glutamatergic neurotransmission. In mice, the constitutive knockdown of NMDA
receptors leads to social deficits, repetitive behavior, and self-injurious responses that reflect
aspects of the autism clinical profile. However, social phenotypes differ with age: mice with
reduced NMDA-receptor function exhibit hypersociability in adolescence, but markedly deficient
sociability in adulthood. The present studies determined whether acute disruption of NMDA
neurotransmission leads to exaggerated social approach, similar to that observed with constitutive
disruption, in adolescent C57BL/6J mice. The effects of MK-801, an NMDA receptor antagonist,
were compared with amphetamine, a dopamine agonist, and fluoxetine, a selective serotonin
reuptake inhibitor, on performance in a three-chamber choice task. Results showed that acute
treatment with MK-801 led to social approach deficits at doses without effects on entry numbers.
Amphetamine also decreased social preference, but increased number of entries at every dose.
Fluoxetine (10 mg/kg) had selective effects on social novelty preference. Withdrawal from a
chronic ethanol regimen decreased activity, but did not attenuate sociability. Low doses of
MK-801 and amphetamine were also evaluated in a marble-burying assay for repetitive behavior.
MK-801, at a dose that did not disrupt sociability or alter entries, led to a profound reduction in
marble-burying. Overall, these findings demonstrate that moderate alteration of NMDA,
dopamine, or serotonin function can attenuate social preference in wild type mice.
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1. Introduction
Autism spectrum disorders (ASDs) are a set of etiologically diverse neurodevelopmental
syndromes characterized by three core symptoms: social interaction deficits, impaired
communication, and restricted repetitive behavior. A strong heritable component for
susceptibility to ASD has been supported by high concordance rates between monozygotic
twins (Bailey et al. 1995, Folstein and Rosen-Sheidley 2001, Rosenberg et al. 2009).
However, genetic and epidemiological studies have provided growing evidence for the
importance of environmental factors in the development of the disorder (Hallmayer et al.
2011). For example, autism risk factors include maternal use of pharmaceutical agents with
neurotoxic effects (Rasalam et al. 2005, Williams et al. 2001), maternal immune response to
infection (Libbey et al. 2005), or exposure to environmental pollutants (Palmer et al. 2006,
Shelton et al. 2012, Tian et al. 2011, Volk et al. 2011). A review by Herbert et al. (2006)
identified 135 genes that have been shown to mediate responses to environmental challenge,
and that are located within autism linkage regions. Overall, a complex combination of
genetic predisposition and environmental contribution may underlie the broad range and
differential severity of symptoms in autism.
Although the mechanistic basis for the abnormal behavioral profiles in ASD is not yet
known, genetic analyses in human populations have implicated several genes important for
synaptic function, including SHANK3, which encodes a member of the post-signaling
complex of glutamatergic synapses, and GRIN1, which encodes the obligatory NMDAR1
subunit of the NMDA (N-methyl-D-aspartate) receptor (Abrahams and Geschwind 2008,
Geschwind 2011, Voineagu et al. 2011). Dysregulation of excitatory and inhibitory
signaling in brain has been implicated in ASD (Rubenstein 2010), suggesting that abnormal
neurotransmission induced by environmental factors could exacerbate genetic predisposition
for core symptoms. In line with this premise, work in rodent models has demonstrated that
developmental exposure to neurotoxins can have long-term effects on glutamate, dopamine,
and serotonin function, including altered sensitivity to the behavioral effects of NMDA
receptor antagonists (Basta-Kaim et al. 2011, Fortier et al. 2004, Graham et al. 2012, Moy
and Breese 2002, Ozawa et al. 2006, Shi et al. 2003, Vorhees et al. 2012, Zuckerman et al.
2003).
The acute administration of NMDA receptor antagonists can decrease rodent social
interaction, as well as induce stereotyped, perseverative responses (Corbett et al. 1995, De
Moura Linck et al. 2008, Gao et al. 2009, Nilsson et al. 2006, Nilsson et al. 2001, Steinpreis
et al. 1994). Mice with reduced function of Grin1 recapitulate many ASD features, including
overt social deficits, abnormal repetitive behavior, self-injurious responses, sensory hyper-
reactivity, and impaired sensorimotor gating (Duncan et al. 2004, Halene et al. 2009, Mohn
et al. 1999, Moy et al. 2008a, Moy et al. 2012). However, most of these changes have been
reported in adult mice. We have recently found that, in contrast to a marked lack of
sociability in adulthood, Grin1 knockdown mice have significant hypersociability during
adolescence (Moy et al. 2012). Further, there is preliminary evidence that memantine, an
NMDA antagonist, can increase social interaction in subjects with autism (Doyle and
McDougle 2012). The following studies examined whether acute disruption of NMDA
receptor function in adolescent C57BL/6J mice (ages 5 to 7 weeks) leads to exaggerated
social preference, similar to that observed with constitutive reduction of NMDA receptors,
in a three-chamber choice task.
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Significant impairment of social interaction has also been reported following dysregulation
of dopaminergic (Gendreau et al. 1998, Gendreau et al. 2000, Rodriguiz et al. 2004,
Steinpreis et al. 1994) and serotonergic (Homberg et al. 2007, Zhuang et al. 1999; for
reviews, see Gingrich and Hen 2001, Insel and Winslow 1998) neurotransmission in animal
models. Therefore, the effects of MK-801 (Dizocilpine), an NMDA receptor antagonist, on
social approach were compared to those of amphetamine, a dopamine agonist, and
fluoxetine, a selective serotonin reuptake inhibitor. In addition, the role of anxiety in social
deficits was investigated by testing mice following withdrawal from chronic ethanol, which
has been shown to induce anxiety-like behavior and social interaction deficits in rats (File et
al. 1993, Knapp et al. 2004, Moy et al. 1997, Wills et al. 2010).
The marble-burying assay has been proposed as a measure of perseverative motor responses,
relevant to abnormal repetitive behavior in autism, obsessive-compulsive disorder, and other
neuropsychiatric conditions (Jimenez-Gomez et al. 2011, Londei et al. 1998, Takeuchi et al.
2002, Thomas et al. 2009). Although Grin1 knockdown mice exhibit hyperactivity and
increased stereotypy, including over-grooming to the point of self-injury, they have
profound deficits in marble-burying (Riddick et al. 2011). Similarly, MK-801 treatment in
ICR mice has been shown to attenuate marble-burying, but at a dose with significant
stimulant effects on locomotor activity (Egashira et al. 2008). The present studies
determined the effects of MK-801 and amphetamine on marble-burying at low doses that did
not alter sociability or, in the case of MK-801, change entries in the social approach task.
2. Material and methods
2.1. Animals
Sets of male C57BL/6J mice (n = 12–24 mice) were purchased from the Jackson Laboratory
(JAX; Bar Harbor, ME), or obtained from C57BL/6J breeding pairs from JAX. Mice
received from JAX were 3 to 4 weeks of age upon arrival, and were given one week to
acclimate to the new housing conditions. Mice were group-housed in ventilated cages, and
given free access to water and Prolab RMH 3000 chow, or water and liquid diet for the
ethanol study (described below). The housing room had a 12-hr light/dark cycle (lights off at
7:00 p.m.). All procedures were conducted in strict compliance with the policies on animal
welfare of the National Institutes of Health (stated in the “Guide for the Care and Use of
Laboratory Animals,” Institute of Laboratory Animal Resources, National Research
Council, 1996 edition) and the University of North Carolina.
2.2 Study design
2.2.1 Effects of altered NMDA, dopamine, or serotonin function on social
approach—4–5 separate sets of mice (JAX) were used to test each compound: MK-801
(0.2, 0.3, or 0.5 mg/kg), amphetamine (1.0, 2.0, or 3.0 mg/kg), and fluoxetine (5.0, 10.0, and
20.0 mg/kg), with at least half of the subjects from each separate set treated with vehicle. At
4–5 weeks in age, mice were given a one-hour open-field session, without any drug
treatment. This procedure served to familiarize mice with the laboratory setting and with
exploration of a novel environment. At 5–7 weeks of age, each mouse was given a single
drug or vehicle treatment, and then tested in the 3-chamber choice task for social approach.
A separate set of mice (n = 25; JAX) was tested with vehicle and fluoxetine (10 mg/kg), to
confirm selective drug effects observed in the first group. For each test, experimenters were
blinded to drug treatment condition.
2.2.2 Effects of ethanol withdrawal on social approach—At 5–6 weeks of age,
mice (n = 8; JAX) were weighed, housed 2 per cage, and placed for 14 days on a modified
Lieber-DeCarli liquid diet (PMI Micro-Stabilized Alcohol Rodent Liquid Diet; Test Diet,
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Richmond, IN). The diet included 5% sucrose to increase palatability. Mice continued to
have free access to water throughout the liquid diet regimen. For the first 2 days of the
regimen, all mice were given regular liquid diet. The control group (n = 4) remained on this
diet for the entire regimen. For the ethanol-withdrawal group (n = 4), mice were introduced
to liquid diet containing 2.4% ethanol for 2 days, and then received 4.8% ethanol for the
following 10-day period. The amount of diet given to the control group was matched to the
mean amount of diet consumed by the ethanol-treatment group on the previous day, to
insure both groups were drinking the same overall amount. On the morning of the test day,
the ethanol liquid diet was replaced with regular liquid diet to induce withdrawal in the
ethanol-exposed mice. 5–6 hours after replacement of the ethanol diet, mice were evaluated
in the 3-chamber test for sociability, but not the test for social novelty (due to time
constraints of the withdrawal period).
2.2.3 Effects of reduced NMDA-receptor function on marble-burying—Two sets
of mice were evaluated for MK-801 effects on marble-burying. Subjects in the first set were
experimentally-naïve, male C57BL/6J mice (n = 24), bred in the UNC animal facility. Each
mouse received one test with either MK-801 (0.2 or 0.3 mg/kg) or vehicle (n=8 per
treatment group). Subjects in the second set were 25 C57BL/6J mice (JAX) first used to
confirm effects of fluoxetine (10 mg/kg) in the social approach test. One-two weeks
following the social test, mice were re-assigned to 3 treatment groups (0.05 or 0.1 mg/kg
MK-801, or vehicle, with 8–9 mice per group), balanced for initial fluoxetine or vehicle
exposure, and assessed for marble-burying.
2.2.4 Effects of enhanced dopamine function on marble-burying—Subjects were
experimentally-naïve, male C57BL/6J mice (n = 21), bred in the UNC animal facility. Each
mouse first received one marble-bury test with either amphetamine (1.0 or 2.0 mg/kg) or
vehicle (n = 7 per treatment group). One week later, all subjects were re-assigned to 2 new
treatment groups (balanced for initial drug exposure), and re-tested in the marble-bury assay.
Treatments for this second test were 1.5 mg/kg amphetamine (n=10 mice), and vehicle
(n=11 mice).
2.3 Testing procedures
2.3.1 Three-chamber social choice test—Mice were tested in an automated 3-
chamber box, using our published methods (Moy et al. 2004, Moy et al. 2007, Nadler et al.
2004). Dividing walls had retractable doorways allowing access into each chamber. The
automated box had photocells embedded in each doorway to allow quantification of entries
and duration in each chamber of the social test box. The chambers of the apparatus were
cleaned with water and dried with paper towels between each subject. At the end of each test
day, the apparatus was sprayed with 70% ethanol and wiped clean with paper towels. The
choice test had 3 consecutive 10-min phases, conducted in the same test session:
1. Habituation. The test mouse was first placed in the middle chamber and allowed to
explore, with the doorways into the two side chambers open.
2. Sociability. After the habituation period, the test mouse was enclosed in the center
compartment of the social test box, and an unfamiliar mouse (stranger 1; a male
C57BL/6J adult) was enclosed in a wire cage (Galaxy Cup, Spectrum Diversified
Designs, Inc., Streetsboro, Ohio) and placed in a side chamber. All stranger mice
had been previously habituated to the wire cage across at least 3 days (5 min per
day on the first 2 days, and 10 min on day 3). The location for stranger 1 alternated
between the left and right sides of the social test box. An empty wire cage was
placed in the opposite side, to serve as a novel object control. Following placement
of stranger 1, the doors were re-opened, and the subject was allowed to explore the
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entire social test box. Measures were taken of the amount of time spent in each
chamber and the number of entries into each chamber by the automated testing
system. In addition, the amount of time spent sniffing each of the wire cages was
recorded by a human observer.
3. Preference for social novelty. At the end of the sociability test, each mouse was
further tested for preference to spend time with a more-novel stranger. A new
unfamiliar mouse (stranger 2) was placed in the wire cage that had been empty
during the previous session. The test mouse then had a choice between the first,
already-investigated mouse (stranger 1) and the novel unfamiliar mouse (stranger
2). The same measures were taken as with the sociability test.
2.3.2 Marble-burying assay—Mice were tested in a standard housing cage located in a
sound-attenuating chamber with houselight and fan. The cage contained 5 cm deep corncob
bedding, with 20 black glass marbles (14 mm diameter) arranged in an equidistant 5 × 4 grid
on top of the bedding. Animals were given access to the marbles for 30 min. Measures were
taken of the number of buried marbles (2/3 of the marble covered by the bedding) by an
observer blind to drug treatment.
2.4 Drugs
MK-801 ((+)-MK-801 hydrogen maleate), amphetamine (D-amphetamine sulfate), and
fluoxetine HCL were purchased from Sigma Chemicals (St. Louis, IL), and administered
either 20 min (MK-801 and fluoxetine) or 10 min (amphetamine) before a 10-min
habituation period in the social test box. Low to moderate doses of MK-801 and
amphetamine were used to minimize confounding locomotor effects. Fluoxetine treatment
included doses found to be anxiogenic in mice tested on the elevated plus maze (10 mg/kg;
(Uz et al. 2004)) or in a novel-box environment (20 mg/kg; (Belzung et al. 2001)). Dose
concentration was based on the salt weight of each compound. Ethanol was administered as
described in section 2.2.2 and published reports (Parnell et al. 2007).
2.5 Data analysis
Statview (SAS Inc., Cary, NC) was used for data analyses. One-way or repeated measures
Analysis of Variance (ANOVAs) were used to determine effects of drug dose on social
behavior and marble-burying. Post-hoc comparisons to vehicle means were conducted with
Fisher’s Protected Least Significant Difference (PLSD) tests only when significant treatment
effects were found in the overall ANOVAs. Within-dose group repeated measures ANOVAs
were used to determine side preferences in the social approach assay. For all comparisons,
significance was set at p < 0.05.
3. Results
3.1 Effects of MK-801 on social approach
3.1.1 Sociability—The results showed that treatment with MK-801 could attenuate social
preference at doses that had no effects on exploration during the social approach task. In the
sociability test (Figure 1A,B), highly significant effects of MK-801 were observed for time
spent in each side [main effect of treatment, F(3,53)=15.35, p<0.0001] and sniffing at each
cage [main effect of treatment, F(3,53)=8.94, p<0.0001, treatment x side interaction,
F(3,53)=6.67, p=0.0007]. At a dose of 0.3 mg/kg, mice no longer demonstrated a significant
preference for the stranger side, in comparison to an empty cage. However, this dose did not
alter number of entries [Figure 2A; post-hoc tests following main effect of treatment,
F(3,53)=4.8, p=0.005], suggesting that the changes in social interest were not due to a lack
of exploration during the test.
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3.1.2 Social novelty—The control groups given vehicle showed the predicted shift in
preference to the newly-introduced stranger 2 in the social novelty test (Figure 3A,B).
Treatment with MK-801, even at the low 0.2 mg/kg dose, disrupted this shift in preference,
whether measured by time in each side [main effect of treatment, F(3,53)=7.83, p=0.0002]
or sniffing at each cage [main effect of treatment, F(3,54)=3.12, p=0.0336, treatment x side
interaction, F(3,54)=3.96, p=0.0127]. At the same time, only the highest dose of MK-801
led to a change in number of entries during the social novelty test [Figure 2B; post-hoc tests
following main effect of treatment, F(3,53)=2.99, p=0.039]
3.2 Effects of amphetamine on social approach
3.2.1 Sociability—Amphetamine did not disrupt sociability to the same extent as MK-801
(Figure 1C,D). A repeated measures ANOVA did not reveal any significant effects of
amphetamine treatment on time spent in each side, although mice no longer demonstrated a
significant preference for the side with the stranger 1 mouse at the two higher doses (2.0 and
3.0 mg/kg). This trend towards reduced social approach following amphetamine treatment
was significant when measured by time spent sniffing each wire cage [main effect of
treatment, F(3,66)=4.63, p=0.0053; treatment x side interaction, F(3,66)=3.78, p=0.0144].
Amphetamine had strong stimulant effects during the social approach test (Figure 2C), with
higher numbers of entries observed in the test for sociability at every drug dose [main effect
of treatment, F(3,66)=29.63, p<0.0001].
3.2.2 Social novelty—In the test for social novelty preference (Figure 3C,D), there were
no significant effects of amphetamine treatment on either time spent in each side, or time
spent sniffing each wire cage. However, none of the groups treated with amphetamine
demonstrated a preference for spending more time in the side containing the newly-
introduced stranger 2 (Figure 3C). As in the first phase of testing, amphetamine led to overt
increases in entries [Figure 2D; main effect of treatment, F(3,66)=21.52, p<0.0001].
3.3. Effects of fluoxetine on social approach
Previous studies have reported that, at a dose of 10 mg/kg, fluoxetine increases low levels of
sociability in BTBR T+tf/J mice, a model for autism-like behavior (Chadman 2011, Gould
et al. 2011), but at a higher dose (30 mg/kg), fluoxetine reduces social preference in C57BL/
6J mice (Chadman 2011). In the present study, fluoxetine led to decreased sociability in
C57BL/6J mice (Figure 1E,F), but this effect was not consistent with increasing drug dose.
In particular, mice treated with the low (5 mg/kg) or high (20 mg/kg) doses of fluoxetine
spent significantly less time sniffing at the cage containing the stranger mouse [post-hoc
tests followed repeated measures ANOVA; main effect of treatment, F(3,53)=4.72,
p=0.0054; trend for significant treatment x side interaction, F(3,53)=2.66, p=0.0579].
Further examination of the data indicated the 10 mg/kg dose of fluoxetine did not alter
sociability but, in the social novelty test, attenuated preference for spending more time with
the second stranger (Figure 3E). This selective sparing of sociability with concomitant
disruption of social novelty preference by a moderate dose of fluoxetine was replicated in a
separate set of adolescent mice (Figure 4). Fluoxetine did not change number of entries
during the social approach task at any dose in the first sets of mice (Figure 2E,F), or in the
separate set tested with the 10 mg/kg dose (data not shown).
3.4 Social approach during withdrawal from chronic ethanol
Although the subject numbers in the treatment groups were low (4 control diet and 4 ethanol
diet mice), the results clearly indicated that withdrawal from chronic ethanol did not disrupt
sociability, but did lead to overt reductions in exploration (Figure 5). Both the control group
and the withdrawal group had strong preference for spending more time in the side
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containing the stranger mouse [within-group analyses following significant effect of side in
overall ANOVA, F(1,6)=110.68, p<0.0001] and sniffing the stranger’s cage [effect of side
in overall ANOVA, F(1,6)=97.03, p<0.0001]. Although chronic ethanol exposure did not
alter sociability, the ethanol-withdrawal group had significantly fewer entries between sides,
in comparison to the control diet mice [main effect of treatment, F(1,6)=16.0, p=0.0071;
treatment x side interaction, F(1,6)=8.33, p=0.0278].
3.5 MK-801 and amphetamine effects on marble-burying
3.5.1 MK-801 disruption of marble-burying—The marble-burying assay has been
proposed as a measure of perseverative motor responses (Jimenez-Gomez et al. 2011,
Londei et al. 1998, Takeuchi et al. 2002, Thomas et al. 2009). Treatment with MK-801 led
to marked decreases in marble-burying (Figure 6), even at doses that did not disrupt
sociability or alter exploration during the social test. Highly significant effects of MK-801
(0.2 and 0.3 mg/kg) were found for the first set of mice [F(2,21)=23.44, p<0.0001]. Because
the lower dose of MK-801 (0.2 mg/kg) almost eliminated marble-burying, a separate set of
mice were evaluated with even lower doses. The results showed that 0.1 mg/kg, but not 0.05
mg/kg, also significantly reduced marble-burying [post-hoc tests following 1-way ANOVA,
F(2,22)=7.97, p=0.0025].
3.5.2 Amphetamine disruption of marble-burying—The initial results with
amphetamine indicated a steep dose-response function, with no change at a dose of 1.0 mg/
kg, and a virtual loss of marble-burying at 2.0 mg/kg [post-hoc tests following 1-way
ANOVA, F(2,18)=20.37, p<0.0001]. Therefore, one week following the first test, mice were
re-evaluated with either vehicle or 1.5 mg/kg amphetamine. The results showed that a partial
loss of marble-burying occurred at the mid-point dose, confirming an orderly relationship
between dose and response [F(1,19)=19.37, p=0.0003].
4 Discussion
The present studies demonstrate that modest alterations in glutamatergic, dopaminergic, or
serotonergic function by treatment with neuroactive compounds can disrupt social
preference in adolescent mice, dependent on dose and behavioral measure. MK-801,
amphetamine, and fluoxetine all led to a loss of significant social preference, measured by
time spent in each side chamber. Further, all three compounds decreased sniffing directed
toward a stranger mouse during a test for sociability. However, only MK-801, at a dose of
0.3 mg/kg, attenuated preference for sniffing a stranger mouse versus a non-social novel. In
the test for social novelty, MK-801 (at every dose) abolished preference for the less familiar
second stranger, whether measured by time in proximity or time spent sniffing. Low doses
of MK-801 (0.2 mg/kg) or amphetamine (2.0 mg/kg) markedly reduced the number of
marbles buried in a typically robust digging assay, used to model the restricted interests and
repetitive behavior characteristic of autism. Overall, the results suggest that both social
approach and exploration of novelty are particularly susceptible to disruption by aberrant
glutamate function, which could be relevant to mechanisms in autism core symptoms.
4.1 MK-801 and amphetamine effects on social approach
Genetic reduction of NMDA receptor function can disrupt social approach. Several studies
have shown that mice with reduced expression of the NR1 NMDA receptor subunit
(encoded by the Grin1 gene) have marked deficiencies in social behavior, including a lack of
sociability in the three-chamber choice task (Duncan et al. 2004, Halene et al. 2009, Mohn et
al. 1999, Moy et al. 2012). However, we have recently found that the sociability deficits are
dependent upon age: when tested in adolescence, Grin1 mutant mice demonstrate overt
hypersociability, rather than a lack of social preference (Moy et al. 2012), raising the
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possibility that decreased NMDA neurotransmission could have a pro-social effect in young
mice. The present findings indicate that treatment with MK-801 leads to deficits in social
approach at doses that do not alter exploration and activity during the test. Acute treatment
with amphetamine also attenuated social preference, but at doses that increased activity
during the test. While both MK-801 and amphetamine significantly decreased sniffing
directed towards the stranger mouse in the sociability test, only MK-801 significantly
attenuated sniffing directed towards the empty wire cage. These results suggest that
MK-801, but not amphetamine, disrupted both social motivation and a more general drive
towards novel stimuli, in line with the loss of preference for the second, less-familiar
stranger mouse observed at every MK-801 dose.
4.2 Effects of fluoxetine and withdrawal from chronic ethanol on social approach
SLC6A4, which encodes the serotonin transporter (also known as 5-HTT or SERT), has
been implicated as an autism susceptibility gene in multiple studies (Coutinho et al. 2007,
Devlin et al. 2005, Kistner-Griffin et al. 2010, Sutcliffe et al. 2005, Wassink et al. 2007). We
have previously found that loss of Slc6a4 in mice leads to significant reductions in
sociability (Moy et al. 2008b). Although chronic treatment with fluoxetine, a selective
inhibitor of the serotonin transporter, has antianxiety and antidepressant effects in humans,
acute fluoxetine treatment can have anxiogenic effects in humans (Gorman et al. 1987) and
in mice (Belzung et al. 2001, Uz et al. 2004). The present study showed inconsistent effects
of fluoxetine on social approach. In particular, mice treated with 5.0 or 20.0 mg/kg
fluoxetine did not have significant preference for the side of the test box containing the
stranger mouse; however, a dose of 10 mg/kg appeared to have no effect on sociability, but
attenuated social novelty preference. A second group of mice confirmed the selective effects
of the 10 mg/kg fluoxetine dose. Interestingly, this same dose of fluoxetine has been shown
to increase sociability, but disrupt social novelty preference, in the BTBR T+tf/J (BTBR)
inbred mouse strain, a model of social deficits in autism (Gould et al. 2011; see also
Chadman 2011).
One question was whether acute fluoxetine treatment had anxiogenic effects in the
adolescent mice. Chadman (2011) has shown that fluoxetine (10 and 30 mg/kg) does not
change percent time spent on the open arms of an elevated maze, a standard measure of
anxiety-like behavior, in either BTBR or C57BL/6 adult mice. In the present study,
fluoxetine did not alter exploration during the three-chamber choice test at any dose,
suggesting that the changes in social approach were not explained by increased anxiety-like
behavior. To further determine possible effects of enhanced anxiety on social approach, we
tested mice during withdrawal from a chronic ethanol regimen. Previous work in rat models
has shown that ethanol withdrawal leads to anxiety-like responses in the elevated plus maze
and decreased social interaction (File et al. 1993, Knapp et al. 2004, Moy et al. 1997, Wills
et al. 2010). Although only four mice were evaluated following ethanol exposure, levels of
sociability were robustly significant. At the same time, the withdrawal group had overt
reductions in entries during the test, indicating that the ethanol exposure had selective,
detrimental effects on exploration, but not social approach. Overall, the findings do not
support increased anxiety as a factor in the reduced social preference observed with
MK-801, amphetamine, or fluoxetine.
4.3 Selective disruption of social novelty preference
The selective effects of fluoxetine (10 mg/kg) on social novelty preference, versus
sociability, were also evident for MK-801 and amphetamine. At the lowest doses, MK-801
(0.2 mg/kg) and amphetamine (1.0 mg/kg) did not attenuate preference for the stranger
mouse versus a novel object in the sociability test, but did prevent a preference for stranger
2, in comparison to the more-familiar stranger 1, in the social novelty task. A similar pattern
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of significant sociability, with a loss of social novelty preference, has been observed in mice
with disruption of the glycine receptor site of the NMDA receptor complex (Labrie et al.
2008), or with partial loss of Neuregulin1, which regulates NMDA receptor function (Moy
et al. 2009). Similarly, treatment with diazepam or scopolamine can selectively disrupt
performance in the social novelty phase of the three-chamber procedure (Riedel et al. 2009).
Motivation in the social novelty task includes a general preference for social proximity and a
more specific preference for social novelty, and the ability to discriminate between a newly-
introduced stranger versus an already-investigated stranger. Thus, the more complex
motivation and demands in this phase could make performance more susceptible to
detrimental effects from even modest alterations in glutamate, dopamine, or serotonin
function.
A drawback to the social novelty task is that the magnitude of preference between two
stranger mice is typically less than the magnitude of preference between social and non-
social stimuli in the sociability phase (present study; Moy et al. 2007). The weaker
preference for stranger 2 in control mice can make the detection of alterations from genetic
or environmental factors more difficult. Our research group has shown that extending the
sociability phase of the three-chamber test to 20 minutes allows greater habituation to the
first stranger, leading to more robust preference for stranger 2 in the first 5 minutes of the
subsequent social novelty task (Nadler et al. 2004). It is notable that Riedel and colleagues
(2009) found significant preference for stranger 2 versus stranger 1 following a 10-minute
delay between the sociability and social novelty phases, demonstrating the utility of the task
as a measure of social memory.
4.4 Effects of MK-801 and amphetamine in the marble-burying assay
Repetitive behavior, including narrow restricted interests, stereotypy, a lack of curiosity
about the environment, and cognitive rigidity, is a core symptom of ASD. The marble-
burying assay has been proposed as a measure for abnormal, perseverative responses in
rodent models (Jimenez-Gomez et al. 2011, Londei et al. 1998, Takeuchi et al. 2002,
Thomas et al. 2009). Increased marble-burying has been reported in BTBR mice (Amodeo et
al. 2012) and in Slitrk5-null mice, which also exhibit stereotyped over-grooming (Shmelkov
et al. 2010). Further, prenatal exposure to valproic acid or maternal immune activation can
also increase marble-burying in mice (Malkova et al. 2012, Mehta et al. 2011). In contrast,
we have found that Grin1 mutant mice have overt reductions in numbers of marbles buried
(Riddick et al. 2011). Similar decreases in marble-burying have been reported in other
mutant lines with autism-like phenotypes (Balemans et al. 2010, Feyder et al. 2010),
suggesting that the assay could be used to model narrow, restricted interests and reduced
exploration, relevant to abnormalities in autism (e.g. Pierce and Courchesne 2001, Sasson et
al. 2008). In the present study, we found that MK-801 and amphetamine, at doses that did
not block significant sociability, led to marked deficiencies in the marble-burying assay.
4.5 Conclusion
These studies demonstrate that acute reductions in NMDA receptor function, or
enhancements in dopaminergic or serotonergic neurotransmission, lead to a dose-dependent
loss of social preference in the three-chamber choice task. None of the compounds resulted
in the hypersociability observed in adolescent mice with constitutive knockdown of NMDA
receptors (Moy et al. 2012). In comparison to amphetamine and fluoxetine, MK-801 induced
greater changes in social approach, including significant treatment effects on the measure of
time spent in each side chamber, a loss of social novelty preference, and decreased
investigation of a non-social novel object. Further, the results from the marble-burying assay
indicate that novelty-induced digging could be a particularly sensitive marker for disruption
of NMDA receptor function. Overall, these findings support the critical role for NMDA
Moy et al. Page 9













receptors in the regulation of social approach and response to novelty in mice, which could
be relevant to the mechanistic basis of ASD symptoms.
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1. Moderate alterations of NMDA, dopamine, or serotonin function attenuated
social preference in adolescent mice.
2. In a three-chamber choice task, preference for social novelty was more
susceptible to disruption than sociability.
3. Withdrawal from chronic ethanol consumption decreased exploration, but had
no effect on sociability, during the choice task.
4. Marble-burying behavior was almost completely attenuated by an MK-801 dose
(0.2 mg/kg) that did not disrupt sociability in adolescent mice.
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Figure 1. Effects of MK-801, amphetamine, and fluoxetine on sociability in adolescent mice
Data shown are means (+ SEM) for 9–10 mice per drug treatment group, and 29–40 mice
per vehicle treatment group. Data for time spent in each side were lost for one mouse from
the MK-801 group, and data for sniffing were lost from three mice (one in the MK-801
group and two in the fluoxetine group), due to equipment failure or experimenter
error. #Vp<0.05, comparison with vehicle. *p<0.05, within-treatment comparison to opposite
side.
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Figure 2. Effects of MK-801, amphetamine, and fluoxetine on entries during the sociability (A,
C, and E) and social novelty (B, D, and F) tests
The measure for entries served as an index for exploration and activity during the 3-chamber
choice task. #Vp<0.05, comparison with vehicle.
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Figure 3. Effects of MK-801, amphetamine, and fluoxetine on social novelty preference
MK-801 attenuated preference for the newly-introduced stranger 2 mouse, in comparison to
the more-familiar stranger 1 mouse, at all doses. #Vp<0.05, comparison with vehicle.
*p<0.05, within-treatment comparison to opposite side.
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Figure 4. Selective disruption of social novelty preference, but not sociability, by fluoxetine (10.0
mg/kg)
Results are from a separate set of C57BL/6J male mice (age 5–6 weeks), tested to confirm
initial findings on fluoxetine effects, shown in Figures 1E and 3E. N = 12 mice treated with
vehicle, and 13 mice treated with fluoxetine. *p<0.05, within-treatment comparison to
opposite side.
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Figure 5. No disruption of sociability during withdrawal from chronic ethanol
Mice were tested 5–6 hours following withdrawal from a 12-day regimen of ethanol liquid
diet, or after exposure to control liquid diet. N = 4 mice per treatment group. #p<0.05,
comparison with group given control liquid diet. *p<0.05, within-group comparison to
opposite side.
Moy et al. Page 20













Figure 6. Dose-dependent attenuation of marble-burying by MK-801 and amphetamine
Data shown are means (+ SEM) from 7–11 mice per vehicle and drug dose, with two
separate sets of mice tested for MK-801 (A and B). Mice given amphetamine received two
tests: a first test (C) with two low drug doses (1.0 and 2.0 mg/kg), and a second test (D), one
week later, with a mid-range dose (1.5 mg/kg). Groups in (D) were balanced across drug
treatment in the first test. *p<0.05, comparison to vehicle group. Disruption of social
approach by MK-801, amphetamine, and fluoxetine in adolescent C57BL/6J mice
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